Thanks, Aaron. Could you please provide a link to Audion's latest mixed results? Would that mean Frequency's approach might not work either?
Sorry, my post wasn't clear. Will try again.
First, I'm not sure Audion has released any results much less mixed results.
Second, Audion's approach was founded based at least in part on a paper out of Albert Edge's lab (
http://www.cell.com/neuron/fulltext/S0896-6273(12)00953-1?_returnURL=http://linkinghub.elsevier.com/retrieve/pii/S0896627312009531?showall=true). That paper used a γ-secretase inhibitor which inhibits Notch signalling. Inhibiting Notch was found to transdifferentiate supporting cells into hair cells - i.e., directly transform supporting cells into hair cells. More recently, a paper by Heller and Groves (and co-authors) found that this only worked on young animals (
http://journal.frontiersin.org/article/10.3389/fncel.2015.00110/full). (It's very, very important to pay attention to the age of animals in studies. Does the drug/whatever work on adults or only newborns?) My point was that there are mixed results using using γ-secretase inhibitors to inhibit Notch which is the approach taken by Audion - not that Audion had itself published mixed results.
How does this affect Frequency? A second line of work has looked at changing both Wnt and Notch signalling (e.g.,
https://www.nature.com/articles/srep29418). This work finds that the results are much better when both pathways are manipulated as compared to only 1, and it is increasingly apparent that significant gains are only going to result from the manipulation of multiple signalling pathways.
As far as we know, Frequency's approach (
http://www.cell.com/cell-reports/abstract/S2211-1247(17)30136-5) manipulates both Notch and Wnt signalling (among other things) so it is not subject to the same concern as Audion's approach.
Thus, while I am happy that Audion is starting a trial, I am less confident in their approach than I am in Frequency's.
Hopefully this is clearer.